Home/Pipeline/Malaria

Malaria

Pre-clinicalActive

Key Facts

Indication

Malaria

Phase

Pre-clinical

Status

Active

Company

Keltic Pharma Therapeutics

About Keltic Pharma Therapeutics

Keltic Pharma Therapeutics is a private, preclinical-stage biotech company developing a proprietary drug discovery platform called PEPSMOL©. This platform aims to create 'synthetic biologics' to target hard-to-drug GPCRs, with initial in-house programs targeting severe asthma, malaria, Alzheimer's disease, and schizophrenia. The company, founded by three renowned University of Glasgow professors, is pre-revenue and has secured non-dilutive grant funding, including a SMART Grant from Innovate UK in 2024, to advance its platform and pipeline.

View full company profile

Therapeutic Areas

Inflammatory Diseases Infectious Diseases Neurology Psychiatry

Other Malaria Drugs

Drug	Company	Phase	Status
Vaxine Malaria Vaccine	Vaxine	Preclinical	Active
Malaria Vaccine	VLP Biotech	Pre-clinical	Active
Malaria-on-a-Chip Model	Hesperos	Pre-clinical	Active
Malaria Antibodies	new/era/mabs	Research/Pre-clinical	Active
Dendritic Cell Vaccine	MegaNano BioTech	Pre-clinical	Active
Antibody Programs (Malaria)	Ibex Biosciences	Pre-clinical	Active
Malaria RDTs	Access Bio	Commercial	Active
Malaria Nanobody	VicuTec Biologicals	Pre-clinical	Active